Yahoo
BSE - Delayed Quote INR

Ajanta Pharma Limited (AJANTPHARM.BO)

3,317.75 -76.90 (-2.27%)
At close: 3:29:59 PM GMT+5:30
Chart Range Bar
Loading chart for AJANTPHARM.BO
  • Previous Close 3,394.65
  • Open 3,447.15
  • Bid 3,315.00 x --
  • Ask 3,321.75 x --
  • Day's Range 3,304.45 - 3,447.15
  • 52 Week Range 2,022.05 - 3,447.15
  • Volume 8,793
  • Avg. Volume 7,658
  • Market Cap (intraday) 414.505B
  • Beta (5Y Monthly) 0.16
  • PE Ratio (TTM) 40.90
  • EPS (TTM) 81.11
  • Earnings Date (est.) --
  • Forward Dividend & Yield 56.00 (1.98%)
  • Ex-Dividend Date Nov 10, 2025
  • 1y Target Est 3,207.58

Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company that develops, manufactures, and markets specialty pharmaceutical finished dosages. The company offers chronic and acute therapies; branded generic products; and a range of dosage forms, including tablets, capsules, injectables, inhalers, ointments, creams, and liquids. It also serves various therapeutic areas comprising cardiology, dermatology, ophthalmology, and pain management. The company operates in India, Africa, Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 1973 and is headquartered in Mumbai, India.

www.ajantapharma.com

9,628

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 13.75B
Earnings 2.74B
Profit Margin 19.91%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
5B
10B
19.4%
19.6%
19.8%

Analyst Insights

View More

Analyst Price Targets

2,605.00 Low
3,207.58 Average
3,317.75 Current
3,742.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    19.50%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    52.02B

  • Net Income Avi to Common (ttm)

    10.15B

  • Diluted EPS (ttm)

    81.11

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    9.4B

  • Total Debt/Equity (mrq)

    5.70%

  • Levered Free Cash Flow (ttm)

    --

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: